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Abstract
The relationship between antiphospholipid antibodies (aPL) and sickle cell disease (SCD) has never been systematically addressed.
Our aim was to evaluate potential links between SCD and aPL in all age groups. EMBASE/PubMed was screened from inception to
May 2020 and Peto odds ratios for rare events were calculated. The pooled prevalence (PP) of IgG anticardiolipin antibodies (aCL)
was higher in individuals with SCD than in controls (27.9% vs 8.7%, P < 0.0001), that of IgM aCL was similar in the two groups
(2.9% vs 2.7%); only individuals with SCD were positive for lupus anticoagulant (LA) (7.7% vs 0%, P < 0.0001). The PP of leg ulcers
was similar between aPL positive and negative individuals (44% vs 53%) and between patients in acute crisis and stable patients
(5.6% vs 7.3%). Reporting of aPL as a binary outcome and not as a titer precluded further interpretation. The results indicate that a
prospective case-control study with serial measurements of a panel of aPL in SCD patients might be warranted, in order to
understand further the possible pathogenic role of aPL in SCD.
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Introduction
Sickle cell disease (SCD) is the most common severe mono-
genic disorder in the world. It is characterized at the molecular
level by a valine to glutamic acid transition at position 6 in the
b-globin chain; homozygous mutation affecting the b-globin
chains encoded on both chromosomes (S allele) is responsible
for the presence of hemoglobin (Hb) SS in patients with SCD.
At low oxygen tension Hb SS polymerizes into a fibrous struc-
ture that changes the normally discoid shape of erythrocytes
into a sickle shape. At the clinical level people with Hb SS
undergo acute vaso-occlusive crises in the microcirculation.1
Over time patients with SCD develop a chronic vasculopathy
leading to pulmonary hypertension, ischemic stroke and leg
ulceration.2 In addition, SCD patients have a greater risk of
venous thromboembolism than the general population.3
The pathophysiology of thrombosis as a determinant of
vaso-occlusive crises in SCD patients is known to be multi-
factorial and implication of an autoimmune mechanism is
probably underestimated. It appears that sickle erythrocyte
rigidity may not be the sole pathogenic mechanism underlying
vaso-occlusive crises, as a recent report suggested a contribution
of arteriolar neutrophil-platelet aggregates in the lungs.4 Vascu-
lopathic abnormalities associated with SCD are attributable to
pathways involving vaso-occlusive events and intravascular
hemolysis, which promote inflammation and redox instability.5
The presence and persistence of antiphospholipid antibodies
(aPL) detected via immune or clotting assays in association
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with thrombotic occlusions in any vascular district defines the
antiphospholipid syndrome (APS).6 Pulmonary hypertension7
and leg ulcers8 may also be part of the APS disease spectrum.
An association between IgG anticardiolipin antibodies (aCL)
and recurrent coronary artery disease (CAD) was evidenced by
a recent meta-analysis. Patients with CAD and elevated IgG aCL
had a doubled risk of recurrent major adverse cardiac events at
12 and 24 months.9 A relation was reported also between aPL
and lower extremity peripheral artery disease (PAD), whereas
LA related also to critical limb ischemia and failed revascular-
isation.10 We performed this systematic review to verify whether
aPL occur in individuals with SCD and whether aPL contribute
to the vascular manifestations of SCD.
Materials and Methods
Search Strategy
The systematic review was carried out according to the
PRISMA guidelines.11 MEDLINE and Embase databases were
searched from inception to May 2020 using the following
terms: [‘sickle cell disease’ OR ‘sickle cell anemia’] and
[‘anticardiolipin’ OR ‘anti-beta 2-glycoprotein-I’ OR ‘antipho-
spholipid syndrome,’ OR ‘lupus anticoagulant’ OR ‘lupus
inhibitor’].
Article Selection Criteria
Inclusion criteria were: (i) case-control and/or cohort observa-
tional studies assessing: (a) difference in prevalence or titer of
aPL between individuals with SCD and a control group or
(b) difference in prevalence or titer of aPL between individuals
with SCD with and without vascular occlusions or with and
without leg ulcers; (ii) aPL measured by immune or clotting
assays; and (iii) articles written in any language. Exclusion
criteria were: (i) prevalence studies; (ii) studies not reporting
the relationship between aPL and SCD; and (iii) non-original
research articles. Data were independently extracted into a
standard electronic form and any discrepancies were resolved
by consensus.
Data Processing
Four authors performed the database search. Additional studies
were considered by reading the references of selected articles
(Figure 1). The records were entered into EndNote to remove
duplicates. The same authors screened the primary records for
relevancy and excluded irrelevant articles. The remaining arti-
cles were independently screened by two authors, who
extracted the relevant data into a standard electronic form.
The same authors employed the Newcastle Ottawa Quality
Assessment Scale (NOQAS) to evaluate the quality of non-
Figure 1. PRISMA flow chart showing the study selection process.
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randomized studies. The NOQAS yields scores ranging from 0
to 8 after summing individual scores from three major
domains: (i) selection and comparability of cases and controls;
(ii) exposure of interest; and (iii) outcome of interest.12 Data
extracted included: (i) the country of origin of the study;
(ii) the number of participants; (iii) participant age, sex, Hb
genotype, and eventual vascular involvement (deep vein
thrombosis and presence of leg ulcers); and (iv) type of anti-
body measured (Table 1). At the end of this process, the same
authors reviewed the data jointly. Discrepancies (n¼3) were
resolved by discussion with a third party, until a final consensus
was reached.
Outcome Measures
The primary outcomes were: (i) the comparative pooled pre-
valence (PP) of different aPL in individuals with SCD and
controls; (ii) where possible, the comparative PP of aPL in
individuals with SCD with and without vascular occlusions and
with and without leg ulcers; and (iii) where possible, the stan-
dardized mean difference of aPL titers between the groups
listed in (i) and (ii).
Statistical Analysis
The Peto odds ratio for rare events was used to compare groups
using random effects meta-analyses of categorical and/or contin-
uous outcomes.13 Because the studies identified in the systematic
review were observational, and because of their limited number,
we did not produce funnel plots or use Egger’s test to assess
publication bias. These analyses may be misleading if applied
to fewer than 10 studies.14 Heterogeneity was assessed using the
I2 statistics. Heterogeneity was considered low for I2 < 25%,
moderate for 25% < I2 < 50% and high for I2 > 50%. Statistical
analyses were carried out using Comprehensive Meta-Analysis
(Biostat, Frederick, MD, USA).
Results
Study Number and Vascular Involvement
The initial database search yielded 1076 entries. Another eight
entries were identified after reading the references of selected
articles, thus yielding a total of 1084 entries. After duplicate
removal, 749 records remained. After excluding 721 irrelevant
articles, 28 articles were assessed for eligibility. At the end of
the screening and exclusion process (Figure 1) we identified
11 articles15-25 examining the relationship between aPL and
SCD (Table 1). From one record, we could retrieve only the
abstract because the volume including the article was missing
from the publisher website.18 Likewise, we found only one
article reporting ischemic stroke19 and three articles reporting
leg ulcers,15,19,25 two of which were included in the meta-
analysis.15,25 No articles examined venous thrombosis or any
other vascular involvement.
aPL Tests
aPL were detected by immune or clotting assays depending
on the study. IgG anticardiolipin antibodies (aCL) were
most commonly reported as frequencies of positive
participants15-20,22,24,25 though in two studies IgG aCL were
Table 1. Demographics, Clinical and Laboratory Variables of Participants in Studies Included in the Systematic Review and Meta-Analysis.
Study Country
Study Participants M/F Age SS SC AS aPL CTR M/F Age aPL NOS
type (No.) (No.) (years)a (No.) (No.) (No.) (No.) (No.) (No.) (years)a (No.)
De-Ceulaer
1992
Jamaica CC 108 71/37 25 (11–39) 108 9 116 74/42 0 6
Kucuk 1993 USA CC/CHT 25 19 3 3 2 40 0 5
Liesner 1998 United
Kingdom
CC 96 56/40 9.5 (4–12) 96 6 18 3 7
Nsiri 1998 Tunisia CC 37 18 12 30 2 6
Westerman
1999
USA CC 37 5/15 33 + 5.7 20 17 7 56 0 7
Diatta 2004 Senegal CC 94 59 35 17 39 0 6
Olayemi
2005





CC 100 54/46 16 (1–39) 100 44 50 0 6
Olayemi
2009
Nigeria CHT 66 66 8 5
Toly-Ndour
2011
Congo CC 88 54/34 27 (17–55) 55 25 36 85 41 (24–56) 24 4
Olayimika
2017
Lagos CHT 113 42/71 23 + 11 108 5 9 5
Abbreviations: No, number, M, male; F, female; SS, hemoglobin SS; SC, hemoglobin SC; AS, hemoglobin AS; aPL, antiphospholipid antibody; CTR, controls; NOS,
Newcastle-Ottawa score; CC, case-control; CHT, cohort.
aMedian (interquartile range) or mean + standard deviation is indicated.
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reported in graphical format.19-24 Mean values of IgG aCL in
different groups were reported only in one article.18 One study
indicated the cut-offs for negative, borderline and positive
IgG aCL;20 for this study we summed the numbers of SCD
patients and controls with borderline and positive IgG aCL for
the purpose of the analysis. IgG aCL was measured more than
once in one article.15 Five studies investigated lupus antic-
oagulant (LA) and expressed it as a frequency of positive
participants.21-23,25 LA was assessed via the textarin/ecarin
ratio26 in one study,17 by the kaolin clotting time (KCT)27
Figure 2. Effect size of (A) IgG anticardiolipin antibodies (aCL), (B) IgM aCL and (C) lupus anticoagulant (LA) in participants with sickle cell
disease (SCD) and controls (CTR). 95% CI: 95% confidence interval.
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in three studies21,23,25 and via the activated partial thrombo-
plastin time with hexagonal phospholipid neutralisation28 in
one study.22
Relationship Between aPL and SCD
Eight articles, comprising a total of 472 Hb SS patients and 434
controls, explored the relationship between IgG aCL and SCD.
The PP of IgG aCL was greater in individuals with SCD than
controls (27.9% vs 8.7%), with high heterogeneity (I2 78%, P <
0.0001). All but one study of a pediatric population favored a
positive association between aCL and SCD (Figure 2A). A
sensitivity analysis, performed by removing the pediatric
study,17 resulted in only slightly diminished heterogeneity (I2
71%, P¼ 0.002). However, heterogeneity decreased further by
removing the study of the oldest participants24 (I2 38%, P ¼
0.19), indicating that extremes of age were a potential source of
heterogeneity. Three articles, comprising a total of 170 Hb SS
patients and 143 controls, explored the relationship between
IgM aCL and SCD. The PP of IgM aCL was similar in the two
groups (2.9% vs 2.7%) (Figure 2B). Four studies, comprising a
total of 271 Hb SS patients and 150 controls, explored the
relationship between LA and SCD. LA was detected only in
SCD patients (7.7% vs 0%) (Figure 2C). In one study, neither
individuals with SCD or controls were positive for LA and thus
this study does not appear in the graph.17
Relationship Between aPL and Clinical Manifestations
of SCD
Two articles,15,25 comprising a total of 18 aPL-positive and 149
aPL-negative SCD patients, explored the relationship between
leg ulcers and aPL. One study measured IgG aCL15 and one
measured LA detected via the KCT25: data from these studies
were pooled. The PP of leg ulcers was similar in both groups
(44% vs 53%), with no heterogeneity (Figure 3). A third arti-
cle23 found a slightly but not significantly increased frequency
of LA (measured via KCT) in SCD patients with leg ulcers,
compared with SCD patients without leg ulcers (18.8% vs 6%,
P ¼ 0.1).
Two articles,21,22 comprising a total of 88 individuals with
SCD in acute crisis and 68 individuals with SCD not in acute
crisis, explored the relationship between LA and SCD status.
The PP of LA was similar between individuals with SCD in
crisis and not in crisis (5.6% vs 7.3%). A third study found no
difference between the IgG aCL titers of individuals with SCD
in crisis and not in crisis.19
Discussion
In SCD, reactive oxygen species and lipid peroxidation prod-
ucts accumulate within erythrocytes at each sickling/unsick-
ling cycle, exhausting the antioxidant activities of superoxide
dismutase, catalase and glutathione. The resulting damage
to intracellular structures leads to red cell destruction. Intra-
vascular hemolysis is accompanied by release of several
molecules such as modified hemoglobin, asymmetric
dimethylarginine, and adenine nucleotides that promote vaso-
motor dysfunction and, in the longer term, the proliferative
vasculopathy typical of SCD (reviewed in29). Moreover, anio-
nic phospholipids, including phosphatidylserine, are exposed
on the surface of erythrocytes during hemolysis and may
simultaneously elicit aPL and support coagulation activation,
a key phenomenon in the development of venous thrombosis
in SCD.30 Hence, there is strong interest in understanding the
contribution of aPL in SCD.
Despite a degree of age-related heterogeneity, our meta-
analysis found that the PP of IgG aCL and LA in individuals
with SCD was higher than that in controls, while the PP of IgM
aCL was similar between the two groups. Strangely, the rela-
tionship between aPL and thrombosis was poorly addressed in
the studies included in our meta-analysis. In most studies, it
was difficult to determine whether the average IgG aCL titer of
SCD patients was above or below the thrombogenic threshold
Figure 3. Relationship between antiphospholipid antibodies (aPL) and leg ulcers in individuals with sickle cell disease (SCD) and controls (CTR).
95% CI: 95% confidence interval.
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of 40 IgG phospholipid subunits established in the 1990s, as
very few studies reported average aPL titers. Moreover, studies
assessing changes of aPL after acute sickle crisis did not iden-
tify any differences in these titers compared to the background
status.19,22
Additionally, three studies investigated the relationship
between aPL and leg ulcers, a common feature of SCD vascu-
lopathy. The two studies included in the meta-analysis did not
find any difference in the PP of aPL between individuals with
SCD with leg ulcers and without leg ulcers.15,25 Although the
one study not included in the meta-analysis reported a slightly
but not significantly elevated frequency of LA in SCD patients
with leg ulcers,19 the test employed for detection of LA in two
of these studies was the KCT, a sensitive but poorly specific
assay31 that is no longer recommended for diagnosis of APS.32
In our meta-analysis, we were unable to include an interesting
survey from Oman of 550 SCD patients of whom 14 had co-
morbid APS. Unfortunately, the 14% prevalence of ischemic
stroke in the APS group was not compared with the prevalence
of ischemic stroke in SCD patients without apparent APS, as it
was unclear whether aPL had been tested in this latter group.33
Our meta-analysis had several limitations. First, only a few
studies and their outcomes were included. Second, we were
unable to evaluate publication bias. Third, anti-b2 glycoprotein
I antibodies, which are considered of pathogenic importance in
APS, were not evaluated across the studies reviewed. Fourth,
most studies reported frequencies of participants positive for
aPL but not titers or ratios. Fifth, aPL were measured only at a
single time point in most studies.
Conclusions
Although our meta-analysis revealed a statistical link between
aPL and SCD, the clinical relevance of aPL in SCD remains
unaddressed. From the clinical point of view, checking aPL in
SCD patients with venous thrombosis, ischemic stroke and leg
ulcers may prove rewarding; from the point of view of patho-
genesis, a prospective case-control study taking serial measure-
ments of a wider panel of established and more modern aPL
could be very useful in understanding the possible mechanistic
role of aPL in SCD.
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20. Diatta A, Touré-Fall AO, Sarr NG, et al. Prevalence of antipho-
spholipid antibodies in patients with sickle cell disease. Ann Biol
Clin (Paris). 2004;62(3):291-294.
21. Olayemi E, Halim NKD, Durosinmi MA, Awodu OA. Lupus
anticoagulant in Nigerian children with homozygous sickle cell
disease. Ann Afric Med. 2005;4:122-126.
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